{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:19:47Z","timestamp":1791667187326,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH23FC1010"],"award-info":[{"award-number":["JPMH23FC1010"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eclinm.2024.102952","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:32:42Z","timestamp":1732559562000},"page":"102952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-8665","authenticated-orcid":false,"given":"Tomohiko","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitomi","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-2855","authenticated-orcid":false,"given":"Kinya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ikenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko N.","family":"Minakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1037-3129","authenticated-orcid":false,"given":"Yoshitaka","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2024.102952_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13311-018-00696-y","article-title":"Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias","volume":"16","author":"Buijsen","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102952_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond","volume":"9","author":"Durr","year":"2010","journal-title":"Lancet Neurol"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102952_bib3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1212\/01.wnl.0000325057.33666.72","article-title":"Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms","volume":"71","author":"Schmitz-Hubsch","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102952_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nsmb1215","article-title":"A\u00a0toxic monomeric conformer of the polyglutamine protein","volume":"14","author":"Nagai","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102952_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/ddm311","article-title":"Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic","volume":"17","author":"Takahashi","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102952_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.tins.2008.07.004","article-title":"Polyglutamine neurodegeneration: protein misfolding revisited","volume":"31","author":"Williams","year":"2008","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.eclinm.2024.102952_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.621996","article-title":"Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases","volume":"15","author":"Minakawa","year":"2021","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102952_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jmcb\/mjq005","article-title":"Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?","volume":"2","author":"Takahashi","year":"2010","journal-title":"J\u00a0Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102952_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102952_bib10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102952_bib11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7650","key":"10.1016\/j.eclinm.2024.102952_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102952_bib13","first-page":"707","article-title":"Oligonucleotide therapeutics in neurodegenerative diseases","volume":"15","author":"Scoles","year":"2018","journal-title":"RNA Biol"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102952_bib14","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102952_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7858","key":"10.1016\/j.eclinm.2024.102952_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/d41586-021-01177-7","article-title":"Failure of genetic therapies for Huntington's devastates community","volume":"593","author":"Kwon","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102952_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1212\/WNL.53.1.3","article-title":"CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others","volume":"53","author":"Tournier-Lasserve","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.eclinm.2024.102952_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.639994","article-title":"From genotype to phenotype: expanding the clinical spectrum of CACNA1A variants in the era of next generation sequencing","volume":"12","author":"Indelicato","year":"2021","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102952_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/brainsci7100128","article-title":"Protein misfolding and aggregation as a therapeutic target for polyglutamine diseases","volume":"7","author":"Takeuchi","year":"2017","journal-title":"Brain Sci"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102952_bib20","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/brain\/awaa115","article-title":"Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation","volume":"143","author":"Minakawa","year":"2020","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102952_bib21","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI111640","article-title":"Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis","volume":"74","author":"Brusilow","year":"1984","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102952_bib22","first-page":"2861","article-title":"Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research","volume":"265","author":"Koga","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102952_bib23","first-page":"62","article-title":"Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials","volume":"269","author":"Choi","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102952_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jnnp-2019-322168","article-title":"Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials","volume":"91","author":"Nishizawa","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102952_bib25","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-Hubsch","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102952_bib26","first-page":"591","article-title":"Reliability of the Japanese version of the scale for the assessment and rating of ataxia (SARA)","volume":"61","author":"Sato","year":"2009","journal-title":"Brain Nerve"},{"key":"10.1016\/j.eclinm.2024.102952_bib27","series-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102952_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0165-1781(02)00106-3","article-title":"Cross-cultural validation of the Beck depression inventory-II in Japan","volume":"110","author":"Kojima","year":"2002","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102952_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1524-4733.2008.00449.x","article-title":"Assessing items on the SF-8 Japanese version for health-related quality of life: a psychometric analysis based on the nominal categories model of item response theory","volume":"12","author":"Tokuda","year":"2009","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102952_bib30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","article-title":"Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study","volume":"14","author":"Jacobi","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102952_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1545968311412053","article-title":"Impaired motor learning by a pursuit rotor test reduces functional outcomes during rehabilitation of poststroke ataxia","volume":"26","author":"Hatakenaka","year":"2012","journal-title":"Neurorehabil Neural Repair"},{"key":"10.1016\/j.eclinm.2024.102952_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1750-1172-8-177","article-title":"Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study","volume":"8","author":"Ashizawa","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102952_bib33","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/acn3.51875","article-title":"Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset","volume":"10","author":"Jacobi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.eclinm.2024.102952_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-014-0118-4","article-title":"A\u00a03-year cohort study of the natural history of spinocerebellar ataxia type 6 in Japan","volume":"9","author":"Yasui","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102952_bib35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/mds.29788","article-title":"FARS-ADL across ataxias: construct validity, sensitivity to change, and minimal important change","volume":"39","author":"Trasch\u00fctz","year":"2024","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102952_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26479","article-title":"Bridging the gap between statistical significance and clinical relevance: a systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research","volume":"10","author":"Mishra","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102952_bib37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s12311-023-01547-z","article-title":"Consensus recommendations for clinical outcome assessments and registry development in ataxias: ataxia global initiative (AGI) working group expert guidance","volume":"23","author":"Klockgether","year":"2024","journal-title":"Cerebellum"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102952_bib38","first-page":"27","article-title":"A\u00a0simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J\u00a0Basic Clin Pharm"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:34:33Z","timestamp":1764624873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024005315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S2589537024005315"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102952","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102952"}}